Ocular Therapeutix Share Price Today
(NASDAQ: OCUL)

Name: Ocular Therapeutix Share Price Today (NASDAQ: OCUL) - Ocular Therapeutix Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Ocular Therapeutix share price is $7.97 & ₹686.93 as on 25 Jan 2025, 2.30 'hrs' IST

$7.97

▲

-0.01

(-0.13%)

Market is closed - opens 8 PM, 27 Jan 2025

View live Ocular Therapeutix share price in Dollar and Rupees. Guide to invest in Ocular Therapeutix stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Ocular Therapeutix, along with analyst recommendations, forecasts, and comprehensive financials.

Ocular Therapeutix share price movements

Today's Low: $7.81
Today's High: $8.10
$7.97
2.01%
Downside
Day's Volatility :3.52%
Upside
1.54%
52 Weeks Low: $4.01
52 Weeks High: $11.78
$7.97
49.69%
Downside
52 Weeks Volatility :65.94%
Upside
32.31%

Ocular Therapeutix Returns

Period	Ocular Therapeutix Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-29.82%	-3.6%	0.0%
6 Months	-2.33%	-3.9%	0.0%
1 Year	71.24%	3.9%	0.0%
3 Years	45.62%	11.7%	-13.0%

Ocular Therapeutix Key Statistics

in dollars & INR

Previous Close	$7.98
Open	$7.95
Today's High	$8.095
Today's Low	$7.81
Market Capitalization	$1.3B
Today's Volume	$910.8K
52 Week High	$11.775
52 Week Low	$4.01
Revenue TTM	$61.1M
EBITDA	$-110.7M
Earnings Per Share (EPS)	$-1.3
Profit Margin	-226.46%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-72.67%

How to invest in Ocular Therapeutix Stock (OCUL) from India?

It is very easy for Indian residents to invest directly in Ocular Therapeutix from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Ocular Therapeutix stock in both Indian Rupees (INR) and US Dollars (USD). Search for Ocular Therapeutix or OCUL on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Ocular Therapeutix or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Ocular Therapeutix shares which would translate to 0.108 fractional shares of Ocular Therapeutix as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Ocular Therapeutix, in just a few clicks!

Returns in Ocular Therapeutix for Indian investors in Rupees

Investment Value

₹1,00,000

Ocular Therapeutix investment value today

Current value as on today

₹1,74,778

Returns

₹74,778

(+74.78%)

Returns from Ocular Therapeutix Stock

₹71,030 (+71.03%)

Dollar Returns

₹3,748 (+3.75%)

Indian investors sentiment towards Ocular Therapeutix

-38%

Period: Oct 26, 2024 to Jan 24, 2025. Change in 30 Days versus previous period

Search volume for Ocular Therapeutix on INDmoney from India has reduced in the last 30 days as on Jan 25, 2025. -38% less investors are searching Ocular Therapeutix in the last 30 days versus the previous period.

Global Institutional Holdings in Ocular Therapeutix

SUMMER ROAD LLC
9.16%
VR Adviser, LLC
8.12%
Deep Track Capital, LP
8.09%
BlackRock Inc
7.22%
Vanguard Group Inc
5.33%
venBio Select Advisor LLC
5.13%

Analyst Recommendation on Ocular Therapeutix

Buy

85%Buy

14%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Ocular Therapeutix(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Ocular Therapeutix

What analysts predicted

Upside of 128.63%

Target:

$18.22

Current:

$7.97

Insights on Ocular Therapeutix

Price Movement
In the last 1 year, OCUL stock has moved up by 99.0%
Decreasing Revenue
Revenue is down for the last 2 quarters, 16.44M → 15.42M (in $), with an average decrease of 6.2% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -64.84M → -36.49M (in $), with an average increase of 34.1% per quarter
OCUL vs ALNY (3 yr)
In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 101.8% return, outperforming this stock by 60.8%

Ocular Therapeutix Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$2.0M	↑ 3.48%
Net Income	$-57.7M	↓ 8.98%
Net Profit Margin	-2.9K%	↑ 397.1%

	FY19	Y/Y Change
Revenue	$4.2M	↑ 112.41%
Net Income	$-89.9M	↑ 55.89%
Net Profit Margin	-2.1K%	↑ 771.47%

	FY20	Y/Y Change
Revenue	$17.4M	↑ 311.71%
Net Income	$-159.6M	↑ 77.5%
Net Profit Margin	-917.26%	↑ 1210.37%

	FY21	Y/Y Change
Revenue	$43.5M	↑ 150.08%
Net Income	$-10.8M	↓ 93.23%
Net Profit Margin	-24.82%	↑ 892.44%

	FY22	Y/Y Change
Revenue	$51.5M	↑ 18.32%
Net Income	$-63.4M	↑ 487.02%
Net Profit Margin	-123.16%	↓ 98.34%

	FY23	Y/Y Change
Revenue	$58.4M	↑ 13.49%
Net Income	$-80.7M	↑ 27.3%
Net Profit Margin	-138.14%	↓ 14.98%

	Q2 FY23	Q/Q Change
Revenue	$15.2M	↑ 13.55%
Net Income	$-20.7M	↓ 43.18%
Net Profit Margin	-136.19%	↑ 135.96%

	Q3 FY23	Q/Q Change
Revenue	$15.0M	↓ 1.55%
Net Income	$-516.0K	↓ 97.51%
Net Profit Margin	-3.45%	↑ 132.74%

	Q4 FY23	Q/Q Change
Revenue	$14.8M	↓ 0.99%
Net Income	$-29.2M	↑ 5562.79%
Net Profit Margin	-197.41%	↓ 193.96%

	Q1 FY24	Q/Q Change
Revenue	$14.7M	↓ 0.59%
Net Income	$-64.8M	↑ 121.93%
Net Profit Margin	-440.69%	↓ 243.28%

	Q2 FY24	Q/Q Change
Revenue	$16.4M	↑ 11.73%
Net Income	$-43.8M	↓ 32.49%
Net Profit Margin	-266.27%	↑ 174.42%

	Q3 FY24	Q/Q Change
Revenue	$15.4M	↓ 6.18%
Net Income	$-36.5M	↓ 16.64%
Net Profit Margin	-236.58%	↑ 29.69%

	FY18	Y/Y Change
Profit	$1.5M	↑ 4.02%

	FY19	Y/Y Change
Profit	$1.9M	↑ 24.72%

	FY20	Y/Y Change
Profit	$15.3M	↑ 705.47%

	FY21	Y/Y Change
Profit	$39.1M	↑ 155.33%

	FY22	Y/Y Change
Profit	$47.0M	↑ 20.04%

	FY23	Y/Y Change
Profit	$53.2M	↑ 13.22%

	Q2 FY23	Q/Q Change
Profit	$13.9M	↑ 14.16%

	Q3 FY23	Q/Q Change
Profit	$13.6M	↓ 2.23%

	Q4 FY23	Q/Q Change
Profit	$13.4M	↓ 1.16%

	Q1 FY24	Q/Q Change
Profit	$13.4M	↓ 0.2%

	Q2 FY24	Q/Q Change
Profit	$14.9M	↑ 11.52%

	Q3 FY24	Q/Q Change
Profit	$13.9M	↓ 7.15%

	FY18	Y/Y Change
Operating Cash Flow	$-49.2M	↓ 2.47%
Investing Cash Flow	$-1.9M	↓ 106.98%
Financing Cash Flow	$68.6M	↑ 114.45%

	FY19	Y/Y Change
Operating Cash Flow	$-77.6M	↑ 57.59%
Investing Cash Flow	$-2.2M	↑ 18.48%
Financing Cash Flow	$75.3M	↑ 9.76%

	FY20	Y/Y Change
Operating Cash Flow	$-53.6M	↓ 30.97%
Investing Cash Flow	$-841.0K	↓ 62.42%
Financing Cash Flow	$228.0M	↑ 202.64%

	FY21	Y/Y Change
Operating Cash Flow	$-65.6M	↑ 22.4%
Investing Cash Flow	$-1.2M	↑ 41.97%
Financing Cash Flow	$2.9M	↓ 98.75%

	FY22	Y/Y Change
Operating Cash Flow	$-59.6M	↓ 9.07%
Investing Cash Flow	$-3.7M	↑ 211.14%
Financing Cash Flow	$1.5M	↓ 49.0%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-20.1M	↑ 0.51%
Investing Cash Flow	$-2.0M	↓ 41.11%
Financing Cash Flow	$9.6M	↑ 12265.38%

Ocular Therapeutix Technicals Summary

Sell

Neutral

Buy

Ocular Therapeutix is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Ocular Therapeutix Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ocular Therapeutix Inc	-6.56%	-2.33%	71.24%	45.62%	85.58%
Biontech Se	7.34%	41.0%	28.82%	-24.01%	267.83%
Regeneron Pharmaceuticals, Inc.	-3.08%	-35.51%	-26.11%	14.77%	104.65%
Vertex Pharmaceuticals Incorporated	7.08%	-11.73%	2.22%	94.07%	93.4%
Alnylam Pharmaceuticals, Inc.	13.62%	16.62%	53.4%	111.76%	135.44%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ocular Therapeutix Inc	NA	NA	0.0	-1.07	-0.73	-0.22	NA	0.79
Biontech Se	160.8	NA	0.04	-3.33	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	17.02	17.02	1.05	44.99	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.1	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ocular Therapeutix Inc	Buy	$1.3B	85.58%	NA	-226.46%
Biontech Se	Buy	$28.1B	267.83%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.6B	104.65%	17.02	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$110.2B	93.4%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$34.2B	135.44%	NA	-15.86%

About Ocular Therapeutix

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

Organization	Ocular Therapeutix
Employees	267
CEO	Mr. Donald Notman Jr.
Industry	Health Technology

Management People of Ocular Therapeutix

Name	Title
Mr. Donald Notman Jr.	CFO, COO & Principal Accounting Officer
Dr. Jeffrey S. Heier M.D.	Chief Scientific Officer
Dr. Pravin U. Dugel M.D.	Executive Chairman, President & CEO
Dr. Peter K. Jarrett Ph.D.	Chief Technology Officer
Mr. William S. Slattery Jr.	Vice President of Investor Relations
Mr. William H. Ransone II	Vice President of Global Sales & Marketing
Ms. Tracy Smith	Vice President of Human Resources
Mr. Steve Meyers	Chief Commercial Officer
Dr. Peter K. Kaiser M.D.	Chief Development Officer
Mr. Sanjay Nayak MBBS, Ph.D.	Chief Strategy Officer

Important FAQs about investing in Ocular Therapeutix (OCUL) from India :

What is Ocular Therapeutix share price today?

Ocular Therapeutix share price today stands at $7.97, Open: $7.95 ; Previous Close: $7.98 ; High: $8.10 ; Low: $7.81 ; 52 Week High: $11.78 ; 52 Week Low: $4.01. The stock opens at $7.95, after a previous close of $7.98. The stock reached a daily high of $8.10 and a low of $7.81, with a 52-week high of $11.78 and a 52-week low of $4.01.

Can Indians buy Ocular Therapeutix shares?

Yes, Indians can invest in the Ocular Therapeutix (OCUL) from India.

With INDmoney, you can buy Ocular Therapeutix at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Ocular Therapeutix at zero transaction cost.

How can I buy Ocular Therapeutix shares from India?

It is very easy to buy Ocular Therapeutix from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Ocular Therapeutix be purchased?

Yes, you can buy fractional shares of Ocular Therapeutix with INDmoney app.

What are the documents required to start investing in Ocular Therapeutix stocks?

To start investing in Ocular Therapeutix, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.